BÜCHLER, Tomáš, Tomáš PAVLÍK, Zbyněk BORTLÍČEK, Alexandr POPRACH, Rostislav VYZULA, Jitka ABRAHÁMOVÁ a Bohuslav MELICHAR. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Medical Oncology, 2012, roč. 29, č. 5, s. 3321-3324. ISSN 1357-0560. doi:10.1007/s12032-012-0293-x.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma
Autoři BÜCHLER, Tomáš (203 Česká republika), Tomáš PAVLÍK (203 Česká republika, domácí), Zbyněk BORTLÍČEK (203 Česká republika, domácí), Alexandr POPRACH (203 Česká republika), Rostislav VYZULA (203 Česká republika, garant), Jitka ABRAHÁMOVÁ (203 Česká republika) a Bohuslav MELICHAR (203 Česká republika).
Vydání Medical Oncology, 2012, 1357-0560.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Česká republika
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 2.147
Kód RIV RIV/00216224:14110/12:00062519
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1007/s12032-012-0293-x
UT WoS 000311513800046
Klíčová slova anglicky Sunitinib; Sorafenib; Renal cell carcinoma; Response
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 22. 4. 2013 18:49.
Anotace
Patients with metastatic renal cell carcinoma (mRCC) are often treated sequentially with targeted agents, although the optimal strategy is not known. A retrospective, registry-based study has been carried out to assess correlation between clinical response and progression-free survival in patients with mRCC treated sequentially with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. Data on 218 mRCC patients treated with sunitinib and sorafenib who completed therapy with both TKIs were obtained from a database of mRCC patients. Standard nonparametric methods were used to assess correlation between response, PFS and length of treatment on the two agents. A strong correlation between responses to firstversus second TKI was observed (p\0.001). No significant association was noted between the duration of therapy with the two TKIs (p = 0.056), although there was a weak statistically significant correlation between progression- free survival times in the subgroup patients who discontinued treatment because of disease progression. In conclusion, the duration of response on first TKI is of limited value in selecting mRCC patients for sequential TKI therapy. There is a strong correlation between the types of tumour response on the first- versus the second TKI.
VytisknoutZobrazeno: 26. 10. 2020 12:02